PharmaVOICE 2020 Year in Preview features precision medicine insight of CEO of Diaceutics Peter Keeling - Diaceutics

PharmaVOICE 2020 Year in Preview features precision medicine insight of CEO of Diaceutics Peter Keeling

The thought leadership of Peter Keeling, the CEO of Diaceutics, is featured in the PharmaVOICE’s 2020 Year in Preview issue (Nov/Dec 2019). Keeling is one of 130+ precision medicine experts selected to comment on 20 provocative questions regarding changes needed to “address inefficiency and productivity to achieve aspirational goals for healthcare in the future.” 

Keeling’s insight into the future possibilities for precision medicine is featured on page 32 in the opening article, entitled “The Year Ahead.” Keeling responded to the question “What if the promise of personalized medicine was realized?” with the following:

The following quote from Keeling is featured on page 85 in the article entitled “Patient Care: Treatment to Cure,” under “Early detection key to improving health” sidebar:

For more insights on and predictions for Precision Medicine in the year ahead, read the Diaceutics PM Readiness Report. 

Webinars & Podcasts

PharmaVOICE 100 Celebration Marathon
Our Chief Precision Officer, Suzanne Munksted, was delighted to join the PharmaVoice100 panel discussion on Leading Global Teams earlier this month. Catch up on the vibrant discussion around how global organizations and leaders overcome the day...
Diaceutics CEO Peter Keeling's interview on RTE Radio 1 about latest £4m funding round and Precision Medicine
Interview:Diaceutics CEO Peter Keeling interviewed on RTE Radio 1 about latest £4m funding round from Silicon Valley Bank & Precision Medicine
View all

Expert Insights

The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that...
EU IVD Regulation – What does it mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the...
View all expert insights

Competitive Benchmarking Reports

Pharma Precision Medicine Readiness Report 2019
PM Readiness Report 2018 Summary
View all reports


TRK fusion positive cancers: From first clinical data of a TRK inhibitor to future directions
Genetic alterations of neurotrophic tropomyosin or tyrosine receptor kinase (NTRK) 1/2/3 genes generate TRK fusion proteins have been reported in a variety of adult and child cancers from diverse cell/tissue lineages. Larotrectinib, a...
Challenges in the clinical implementation of precision medicine companion diagnostics
The pace of biomarker discovery has increased exponentially over the last few years,ushering in an era of precision medicine (PM) with a growing arsenal of treatments tailored to specific patient populations....
View all publications